ReviewCancer cell international2026
Targeting cell death: a promising approach for colorectal cancer therapy.
Review in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Colorectal cancer is one of the most common digestive malignancies worldwide. Cell death plays a crucial role in maintaining normal biological functions and homeostasis, with dysregulation of cell death leading to tumorigenesis. In addition to apoptosis, necroptosis, pyroptosis and ferroptosis, it is PANoptosis, cuproptosis and disulfidptosis that are involved in the development of CRC. Radiotherapy, chemotherapy, targeted therapy and immunotherapy are the main treatments for advanced CRC. These therapies induce CRC cell death through various pathways, including increased intracellular ROS, induced DNA damage, inhibiting the specific signaling pathways and activating the immune system. Cell death can regulate CRC cells’ sensitivity to treatment through complex mechanisms, suggesting that targeting cell death could not only inhibit rapid CRC cell proliferation but also overcome treatment resistance. This review summarizes the current understanding of various CRC mechanisms and the primary mechanisms by which existing CRC treatments induce cell death. Additionally, we highlight recent research advancements in targeting cell death for CRC treatment and describe numerous challenges encountered in clinical practice. Aiming to provide effective strategies and new perspectives for CRC treatment and to lay a solid theoretical foundation for the development of drugs targeting CRC cell death.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.